Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002472 · ClinicalTrials.gov registry record · Phase 2

Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

A Phase 2 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase

NCT00002472: Completed Phase 2 study, sponsored by Mayo Clinic.

NCT00002472 is a Phase 2 study that has completed, run by Mayo Clinic. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002472, a Phase 2 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and etoposide in treating patients with CNS tumors.

Interventions

  • DRUG cisplatin
  • DRUG etoposide
  • PROCEDURE conventional surgery
  • RADIATION radiation therapy
  • PROCEDURE neoadjuvant therapy

Trial Details

FieldValue
Start Date 1991-03
Est. Completion 2005-08
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00002472

The ClinicalTrials.gov registry entry for NCT00002472 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00002472 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002472 about?

NCT00002472 is a clinical study titled "Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and etoposide in treating patients with CNS tumors.

What is the current status of trial NCT00002472?

This trial is currently completed. It is a Phase 2 study. The study started on 1991-03. Estimated completion is 2005-08.

What interventions are being tested in trial NCT00002472?

The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), neoadjuvant therapy (PROCEDURE).

Who is sponsoring clinical trial NCT00002472?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.